NASDAQ:ANAC - Anacor Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$99.20
Today's Range$99.20 - $99.20
52-Week Range$52.00 - $156.93
VolumeN/A
Average Volume1.81 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Receive ANAC News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ANAC
CUSIP03242010
Phone+1-650-5437500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions

What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

How were Anacor Pharmaceuticals' earnings last quarter?

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) announced its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.01. The biopharmaceutical company earned $17.54 million during the quarter, compared to analyst estimates of $19.53 million. Anacor Pharmaceuticals's revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.30) earnings per share. View Anacor Pharmaceuticals' Earnings History.

Has Anacor Pharmaceuticals been receiving favorable news coverage?

Media stories about ANAC stock have been trending neutral recently, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anacor Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.

How do I buy shares of Anacor Pharmaceuticals?

Shares of ANAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anacor Pharmaceuticals' official website?

The official website for Anacor Pharmaceuticals is http://www.anacor.com.

How can I contact Anacor Pharmaceuticals?

Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.


MarketBeat Community Rating for Anacor Pharmaceuticals (NASDAQ ANAC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel